KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Current Assets (2016 - 2025)

Astrana Health's Current Assets history spans 15 years, with the latest figure at $729.2 million for Q2 2025.

  • For Q2 2025, Current Assets rose 27.84% year-over-year to $729.2 million; the TTM value through Dec 2024 reached $638.5 million, up 38.35%, while the annual FY2024 figure was $638.5 million, 38.35% up from the prior year.
  • Current Assets for Q2 2025 was $729.2 million at Astrana Health, up from -$718.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $729.2 million in Q2 2025 and bottomed at -$718.0 million in Q1 2025.
  • The 5-year median for Current Assets is $461.3 million (2022), against an average of $426.0 million.
  • The largest annual shift saw Current Assets skyrocketed 38.35% in 2024 before it tumbled 233.25% in 2025.
  • A 5-year view of Current Assets shows it stood at $404.5 million in 2021, then increased by 5.85% to $428.1 million in 2022, then rose by 7.8% to $461.5 million in 2023, then surged by 38.35% to $638.5 million in 2024, then increased by 14.2% to $729.2 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's Current Assets are $729.2 million (Q2 2025), -$718.0 million (Q1 2025), and $638.5 million (Q4 2024).